pembrolizumab

JDD Issue Highlights | June 2022: Acne & Rosacea
acne
by NEXT STEPS IN DERM TEAM on
The June 2022 issue of the Journal of Drugs in Dermatology (JDD) focuses on acne and rosacea, with original articles discussing topics such as improving rosacea outcomes in skin of color patients, pediatric and female acne, topical management of facial and truncal acne, and many more. Included in this issue are also case reports on bullous dermatitis and low dose Naltrexone in combination with PRP …

Continue reading "JDD Issue Highlights | June 2022: Acne & Rosacea"

Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab
Oral Mucositis
by NEXT STEPS IN DERM TEAM on
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg …

Continue reading "Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab"

Emerging Use of Immunotherapies for Resectable Melanoma
Melanoma Updates
by Saleh Rachidi, MD, PhD on
Melanoma remains the most common cause of death among skin cancers. Over the past decade, major leaps have been made in treating advanced melanoma, resulting in unprecedented improvement in survival. Nevertheless, a large room for improvement is still ahead. In his presentation Therapeutic Updates in Melanoma: IO for Earlier Stage Disease presented at the 2020 ODAC Dermatology, Aesthetic and Sur …

Continue reading "Emerging Use of Immunotherapies for Resectable Melanoma"

Therapeutic Updates in Melanoma
Melanoma Updates
by NEXT STEPS IN DERM TEAM on
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. David Miller, Instructor in Dermatology and Medicine at Harvard Medical School and member of the Department of Dermatology and the Department of Medicine at Massachusetts General Hospital, where he is co-director of the Merkel cell carcinoma treatment program. Watch as he shares important …

Continue reading "Therapeutic Updates in Melanoma"